For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Archemix Corporation

USPTO Granted Patents = 24

% Expired Patents = 45.8

CIPO Patents = 5

EPO Patents = 15

Forward Citations = 312

Loading Chart...

Loading Chart...

31 inventors (with patents filed for the assignee):

John Louis Diener (15 out of 34 patents)

Charles Wilson (15 out of 16 patents)

David Epstein (12 out of 15 patents)

4. Thomas Greene McCauley (12 out of 14 patents)

5. Claude Benedict (11 out of 12 patents)

6. Markus Kurz (11 out of 18 patents)

7. Jeffrey C Kurz (9 out of 12 patents)

8. James Rottman (8 out of 12 patents)

9. Dilara McCauley (6 out of 44 patents)

10. Dilara Grate (5 out of 5 patents)

11. Kristin Thompson (4 out of 4 patents)

12. H A Daniel Lagassé (4 out of 4 patents)

13. Paul Hatala (3 out of 16 patents)

14. Sara Chesworth Keene (3 out of 3 patents)

15. Anthony Dominic Keefe (3 out of 12 patents)

24 patents: Sort by Forward Citations

1. 10947544 - Aptamer therapeutics useful in the treatment of complement-related disorders (2021-03-16),

2. 10100316 - Aptamers comprising CPG motifs (2018-10-16),

3. 9617546 - Aptamer therapeutics useful in the treatment of complement-related disorders (2017-04-11),

4. 9303262 - Methods for identifying aptamer regulators (2016-04-05),

5. 8946184 - Aptamer therapeutics useful in the treatment of complement-related disorders (2015-02-03),

6. 8853376 - Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics (2014-10-07),

7. 8436164 - Aptamer therapeutics useful in the treatment of complement-related disorders (2013-05-07),

8. 8362234 - Solid support reagents for synthesis (2013-01-29),

9. 8236773 - Aptamer therapeutics useful in the treatment of complement-related disorders (2012-08-07),

10. 8207298 - Methods of separating biopolymer conjugated molecules from unconjugated molecules (2012-06-26),

11. 8105813 - Materials and methods for the generation of fully 2'-modified nucleic acid transcripts (2012-01-31),

12. 8101385 - Materials and methods for the generation of transcripts comprising modified nucleotides (2012-01-24),

13. 8039443 - Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics (2011-10-18),

14. 7998940 - Aptamers to von Willebrand factor and their use as thrombotic disease therapeutics (2011-08-16),

15. 7998939 - Aptamers that bind thrombin with high affinity (2011-08-16),

Archemix Corporation is a biotechnology company specializing in the discovery and development of aptamer therapeutics. Aptamers are single-stranded DNA or RNA molecules that can bind to target molecules with high specificity and affinity. Archemix utilizes its proprietary SELEX platform to identify and optimize aptamers for a wide range of therapeutic applications. The company's innovative approach has the potential to revolutionize drug development and provide novel treatments for various diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

24 Patents

#114 in Cambridge, MA

#829 in Massachusetts

#13,841 in US

#26,555 in the World

Cambridge, MA, United States of America

Archemix Corporation

Forward Citations = 312

31 inventors:

John Louis Diener (15 out of 34 patents)

Charles Wilson (15 out of 16 patents)

David Epstein (12 out of 15 patents)

4. Thomas Greene McCauley (12 out of 14 patents)

5. Claude Benedict (11 out of 12 patents)

Please report any incorrect information to [email protected]

Loading…